US 11,685,789 B2Granted

CD47 antigen-binding molecules

AssigneeHummingbird Bioscience Pte. Ltd.

InventorsJerome Boyd-Kirkup, Dipti Thakkar, Piers Ingram, Zhihao Wu, Konrad Paszkiewicz, Peter Brauer, Siyu Guan

Life of this patent

Estimating the term…

Abstract

CD47 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the CD47 antigen-binding molecules.

Claims11

Dependent claims

An antigen-binding molecule which binds to CD47, comprising:

(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26 and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.

83 more elements

A method of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antigen-binding molecule which binds to CD47and comprises:

(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.

84 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/847,020Filed 22 Jun 2022 · continuation
Priority: GB 17181011 Nov 2017
Published: US 2022/0298254 A110 Nov 2022
Granted: 27 Jun 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61P 35/00
Antineoplastic agents
C07H 21/00
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate

Family

PCT/EP2018/079931Parent of this continuation · filed 1 Nov 2018
US 2022/0356250 A1Pre-grant publication · published 10 Nov 2022
Application16/760,899Parent of this continuation
US 2022/0298254 A1Published application
US 11,685,789 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

CD47 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the CD47 antigen-binding molecules.

An antigen-binding molecule which binds to CD47, comprising:

(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34
or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26 and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(e)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(f)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(g)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
or
(h)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:32
LC-CDR2 having the amino acid sequence of SEQ ID NO:33
LC-CDR3 having the amino acid sequence of SEQ ID NO:142.

83 more elements

Facts

Application

17/847,020Filed 22 Jun 2022 · continuation

Priority

GB 17181011 Nov 2017

Published

US 2022/0298254 A110 Nov 2022

Granted

27 Jun 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61P 35/00
Antineoplastic agents
C07H 21/00
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate

Family

PCT/EP2018/079931Parent of this continuation · filed 1 Nov 2018

US 2022/0356250 A1Pre-grant publication · published 10 Nov 2022

Application16/760,899Parent of this continuation

US 2022/0298254 A1Published application

US 11,685,789 B2This patent

From the US filing history. Foreign family members aren’t listed.